ACHILLES THERAPEUTICS PL-ADR (ACHL)

US00449L1026 - ADR

0.9811  +0 (+0.11%)

After market: 0.98 0 (-0.11%)

Fundamental Rating

3

Overall ACHL gets a fundamental rating of 3 out of 10. We evaluated ACHL against 568 industry peers in the Biotechnology industry. While ACHL has a great health rating, there are worries on its profitability. ACHL has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACHL has reported negative net income.
In the past year ACHL has reported a negative cash flow from operations.
ACHL had negative earnings in each of the past 5 years.
In the past 5 years ACHL always reported negative operating cash flow.

1.2 Ratios

ACHL has a Return On Assets (-54.52%) which is in line with its industry peers.
ACHL has a Return On Equity of -64.84%. This is comparable to the rest of the industry: ACHL outperforms 58.41% of its industry peers.
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROIC N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACHL has more shares outstanding
ACHL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.26, we must say that ACHL is in the distress zone and has some risk of bankruptcy.
ACHL has a Altman-Z score (-3.26) which is in line with its industry peers.
There is no outstanding debt for ACHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.26
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ACHL has a Current Ratio of 6.04. This indicates that ACHL is financially healthy and has no problem in meeting its short term obligations.
ACHL has a better Current ratio (6.04) than 61.06% of its industry peers.
ACHL has a Quick Ratio of 6.04. This indicates that ACHL is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.04, ACHL is doing good in the industry, outperforming 61.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 6.04

More info and screens

1

3. Growth

3.1 Past

ACHL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.70%, which is quite good.
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 0.30% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.97%
EPS Next 2Y22.07%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACHL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ACHL's earnings are expected to decrease with -17.11% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y-17.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACHILLES THERAPEUTICS PL-ADR

NASDAQ:ACHL (12/20/2024, 8:00:00 PM)

After market: 0.98 0 (-0.11%)

0.9811

+0 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners62.46%
Inst Owner Change9.17%
Ins Owners6.51%
Ins Owner ChangeN/A
Market Cap41.90M
Analysts82.22
Price Target2.89 (194.57%)
Short Float %0.36%
Short Ratio1.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.41%
Min EPS beat(2)-14.78%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-46.83%
Min EPS beat(4)-211.02%
Max EPS beat(4)36.52%
EPS beat(8)3
Avg EPS beat(8)-30.26%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)16.48%
EPS NQ rev (3m)16.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-79.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS2.42
TBVpS2.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 6.04
Altman-Z -3.26
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)152.93%
Cap/Depr(5y)462.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y7.97%
EPS Next 2Y22.07%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.14%
OCF growth 3YN/A
OCF growth 5YN/A